|本期目录/Table of Contents|

[1]曾玲玲,韩雪,王昌成.DIAPH3在胰腺癌组织中的表达及其对预后的预测价值[J].国际消化病杂志,2024,03:180-185.
　ZENG LinglingHAN XueWANG Changcheng..Expression of DIAPH3 in pancreatic carcinoma tissues and its prognostic prediction value[J].International Journal of Digestive Disease,2024,03:180-185.
点击复制

DIAPH3在胰腺癌组织中的表达及其对预后的预测价值(PDF)

《国际消化病杂志》[ISSN:1673-534X/CN:31-1953/R]

期数:
2024年03期
页码:
180-185
栏目:
论著
出版日期:
2024-06-25

文章信息/Info

Title:
Expression of DIAPH3 in pancreatic carcinoma tissues and its prognostic prediction value?
作者:
曾玲玲; 韩雪; 王昌成
223003 徐州医科大学附属淮安医院消化科
Author(s):
ZENG Lingling1; 2; 3; HAN Xue1; 2; 3; WANG Changcheng.1; 2; 3
Department of Gastroenterology, the Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'3.an 223003, China
关键词:
胰腺癌; 细胞骨架调节蛋白3; 临床病理特征; 预后
Keywords:
Pancreatic cancer;  Diaphanous related formin Clinicopathological features; Prognosis
分类号:
-
DOI:
10.3969/j.issn.1673-534X.2024.03.009
文献标识码:
-
摘要:
目的探讨细胞骨架调节蛋白3（DIAPH3）在胰腺癌组织中的表达及其对患者预后的预测价值。方法选择2017年3月至2022年3月于徐州医科大学附属淮安医院接受胰腺癌根治术治疗的68例胰腺癌患者纳入研究，收集手术切除的新鲜胰腺癌组织及癌旁组织（距离肿瘤组织边缘＞5cm）。采用免疫组织化学染色法（SP法）检测组织中DIAPH3的表达水平，并分析胰腺癌组织中DIAPH3的表达与患者临床病理特征的关系。采用Cox比例风险回归模型分析探讨胰腺癌患者预后的影响因素。自手术日起对入组患者进行为期1年的随访，采用Kaplan-Meier法绘制生存曲线，以Log-rank检验分析胰腺癌组织中DIAPH3的表达与患者术后1年生存率的关系。采用ROC曲线分析DIAPH3对胰腺癌患者术后1年生存率的预测价值。结果胰腺癌组织中DIAPH3的阳性表达率显著高于癌旁组织（55.88%比14.71%），差异具有统计学意义（χ2＝25.242，P＝0.000）。肿瘤最大径≥3cm、有淋巴结转移、低分化、TNM分期为Ⅲ～Ⅳ期、肿瘤位于胰体/尾部、糖抗原19-9（CA19-9）＞37kU/L者的胰腺癌组织中DIAPH3的阳性表达率分别高于肿瘤最大径＜3cm、无淋巴结转移、中高分化、TNM分期为Ⅰ～Ⅱ期、肿瘤位于胰头部、CA19-9≤37kU/L者，组间差异均有统计学意义（P均＜0.05）。多因素Cox比例风险回归模型分析结果显示，肿瘤最大径、分化程度、CA19-9、DIAPH3均是胰腺癌患者术后1年生存率的独立危险因素（P均＜0.05）。DIAPH3阳性表达组的术后1年生存率低于阴性表达组（55.26%比80.00%），平均生存时间短于阴性表达组[（164.32±18.53）d比（241.54±19.28）d]，差异均有统计学意义（P均＜0.05）。ROC曲线分析结果显示，胰腺癌组织中DIAPH3预测患者术后1年生存率的曲线下面积（AUC）为0.768（95%CI：0.612～0.935），敏感度为82.95%，特异度为63.21%。结论胰腺癌组织中DIAPH3呈高表达，其可能参与了胰腺癌的发生和进展过程，可作为预测患者术后1年生存率的重要参考指标。
Abstract:
Objective? This paper intends to investigate the expression of diaphanous related formin 3 (DIAPH3) in pancreatic carcinoma tissues and its prognostic prediction value. Methods? A total of 68 patients with pancreatic cancer who underwent radical surgery in the Affiliated Huai'an Hospital of Xuzhou Medical University from March 2017 to March 2022 were selected in the study, and the fresh pancreatic carcinoma tissues and paracancerous tissues (＞5 cm away from the tumor tissue margin) were collected. The expression of DIAPH3 in pancreatic carcinoma tissues was detected by immunohistochemical staining (SP method), and the relationship between the expression of DIAPH3 in pancreatic carcinoma tissues and the clinicopathological features of patients was analyzed. The Cox proportional hazards regression model was used to analyze the prognostic factors of pancreatic cancer patients. All patients were followed up for one year from the day of operation. A survival curve was plotted by using the Kaplan-Meier method and a Log-rank test was conducted to compare the 1-year survival rate in patients with DIAPH3 expression in pancreatic cancer. The receiver operating characteristic (ROC) curve was drawn to analyze the predictive value of DIAPH3 on the one-year survival rate of pancreatic cancer patients. Results The positive expression rate of DIAPH3 in pancreatic carcinoma tissues is significantly higher than that in paracancerous tissues (55.88% versus 14.71%), with a statistically significant difference (χ2＝25.242 and P＝0.000). The positive expression rate of DIAPH3 in pancreatic carcinoma tissues with tumor maximum diameter≥3 cm, lymph node metastasis, poor differentiation, TNM stage Ⅲ-Ⅳ, tumor located in the body/tail of the pancreas, CA19-9＞37 kU/L are higher than those with tumor maximum diameter＜3 cm, no lymph node metastasis, medium and high differentiation, TNM stage Ⅰ-Ⅱ, tumor located in the head of the pancreas, CA19-9≤37 kU/L, with statistically significant differences (P＜0.05). The multivariate Cox regression model analysis shows that the largest tumor diameter, differentiation degree, CA19-9, DIAPH3 are independent risk factors for one-year survival rate of patients with pancreatic cancer (P＜0.05). The one-year survival rate of the DIAPH3 positive expression group is lower than that of the negative expression group (55.26% versus 80.00%), and the average survival time is shorter than that of the negative expression group (164.32±18.53 d versus 241.54±19.28 d), with statistically significant differences (P＜0.05). The ROC curve analysis indicates that the area under the curve (AUC) of DIAPH3 in pancreatic carcinoma tissues predicting one-year survival rate of patients is 0.768 (95%CI: 0.612-0.935), the sensitivity is 82.95%, and the specificity is 63.21%. Conclusion DIAPH3 is highly expressed in pancreatic carcinoma tissue, which may participate in the occurrence and progression of pancreatic cancer and become an important reference index to predict the one-year survival rate of patients after surgery.

参考文献/References

1 Cai J, Chen H, Lu M, et al. Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis[J]. Cancer Lett, 2021, 520: 1-11.
2Draper A. Updates in pancreatic cancer: Modest gains and hopeful targets[J]. J Oncol Pharm Pract, 2019, 25(1): 101-109.
3Luo G, Jin K, Deng S, et al. Roles of CA19-9 in pancreatic cancer:Biomarker, predictor and promoter[J]. Biochim Biophys Acta Rev Cancer, 2021, 1875(2): 188409.
4Wood LD, Canto MI, Jaffee EM, et al. Pancreatic cancer:pathogenesis, screening, diagnosis, and treatment[J]. Gastroenterology, 2022, 163(2): 386-402. e1.
5 赵畅, 黄凤祥, 刘盈, 等. DIAPH3基因在肺腺癌中的表达及其对患者生存预后的影响[J]. 河南医学研究, 2021, 30(7): 1157-1161.
6Rong Y, Gao J, Kuang T, et al. DIAPH3 promotes pancreatic cancer progression by activating selenoprotein TrxR1-mediated antioxidant effects[J]. J Cell Mol Med, 2021, 25(4): 2163-2175.
7 中国抗癌协会胰腺癌专业委员会. 胰腺癌综合诊治指南（2018版） [J]. 临床肝胆病杂志, 2018, 34(10): 2109-2120.
8Khalaf N, El-Serag HB, Abrams HR, et al. Burden of pancreatic cancer: from epidemiology to practice[J]. Clin Gastroenterol Hepatol, 2021, 19(5): 876-884.
9 周子建, 孟令威, 吴仲, 等. 胰腺导管腺癌的治疗新进展[J]. 肝胆外科杂志, 2022, 30(5): 328-335.
10 Park W, Chawla A, O'Reilly EM. Pancreatic cancer: a review[J]. JAMA, 2021, 326(9): 851-862.
11 Chen X, Xie L, Qiao K, et al. The pan-cancer analysis identified DIAPH3 as a diagnostic biomarker of clinical cancer[J]. Aging (Albany NY), 2023, 15(3): 689-704.
12 贺国洋, 陈庆庆, 邓美静, 等. DIAPH3对胃癌细胞增殖、迁移和侵袭的影响及分子机制[J]. 中国癌症杂志, 2021, 31(12): 1174-1184.
13 Nishida Y, Nagatsuma AK, Kojima M, et al. Novel stromal biomarker screening in pancreatic cancer patients using the in vitro cancer-stromal interaction model[J]. BMC Gastroenterol, 2020, 20(1): 411.
14 Min L, Ziyu D, Xiaofei Z, et al. Analysis of levels and clinical value of CA19-9, NLR and SIRI in patients with pancreatic cancer with different clinical features[J]. Cell Mol Biol (Noisy-le-grand), 2022, 67(5): 302-308.
15 王成锋. 《中国胰腺癌多学科综合治疗模式专家共识（2020版）》解读[J]. 中华医学信息导报, 2021, 36(9): 23.
16 胡浩, 曲畅, 田孝东, 等. CPDC及SEER数据库中胰腺癌术后患者预后因素的比较研究[J]. 中华外科杂志, 2021, 59(9): 770-776.

备注/Memo

备注/Memo:
通信作者：王昌成，Email: lovefallingsnow@126.com
更新日期/Last Update: 2024-06-25